Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Xp Chemistries AB is currently navigating 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is handled by 1 distinct examiner within 1 distinct art unit. The singular nature of this activity suggests a specific focus for the company's current patent filings, as all activity is localized to one administrative group at the patent office.
The busiest examiner, BAKSHI, PANCHAM, is assigned 1 pending office action. This single action constitutes the total number of pending office actions for the company. With only 1 distinct art unit involved, the prosecution is subject to the standards of one specific administrative group. Practitioners should analyze the specific requirements of BAKSHI, PANCHAM to successfully navigate this Biotechnology & Pharmaceuticals case.
Because the busiest examiner, BAKSHI, PANCHAM, handles the 1 pending office action, there is no internal data to compare examiner behavior within the portfolio. The presence of 1 distinct examiner and 1 distinct art unit creates a centralized prosecution environment. Success for this company depends on tailoring the approach to the specific requirements and interpretive style of this single official in the Biotechnology & Pharmaceuticals sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BAKSHI, PANCHAM | 1 | 76.7% | +30.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18555537 | A process for enzymatic synthesis of amides from amines and carboxylic acids or esters | BAKSHI, PANCHAM | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18555537 | A process for enzymatic synthesis of amides from amines and carboxylic acids or esters | BAKSHI, PANCHAM | — |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18555537 | A process for enzymatic synthesis of amides from amines and carboxylic acids or esters | BAKSHI, PANCHAM | 1623 | §103§112 | Non-Final OA | — | Pending | Oct 15, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialXp Chemistries AB has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Pancham Bakshi has the most, with 1 of Xp Chemistries AB's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.